Hemostemix Inc. announced the source document verification process has been completed and the Company has soft locked the HS 12-01 database. Next, each of the principal investigators will sign off the source documentation of the subjects they followed. Following the sign off by all principal investigators, the HS 12-01 database will be locked. The database includes a total of 65 subjects who were randomized on a 2:1 basis to receive ACP-01 or a placebo, respectively. The Company is seeking the return of all of its intellectual property and assets from Aspire Health Sciences, LLC, including the randomization key(s) required to complete the statistical analyses of the trial.